scholarly journals PD37-08 PHOSPHATIDYLDIGLYCEROL-BASED THERMOSENSITIVE LIPOSOMES SHOW SUPERIOR THERAPEUTIC EFFICACY AGAINST MUSCLE-INVASIVE BLADDER CANCER IN VIVO

2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Iris Brummelhuis ◽  
Michiel Simons ◽  
Lars Lindner ◽  
Simone Kort ◽  
Sytse de Jong ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Therapeutic Efficacy ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Thermosensitive Liposomes ◽  
Muscle Invasive

scholarly journals DPPG2-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment in vivo

2021 ◽  
Vol 38 (1) ◽  
pp. 1415-1424
Author(s):  
Iris S. G. Brummelhuis ◽  
Michiel Simons ◽  
Lars H. Lindner ◽  
Simone Kort ◽  
Sytse de Jong ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Bladder Cancer ◽  
Cancer Treatment ◽  
Drug Delivery System ◽  
Delivery System ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Thermosensitive Liposomes ◽  
Muscle Invasive

scholarly journals In vivo Evaluation of Mucoadhesive Nanoparticulate Docetaxel for Intravesical Treatment of Non–Muscle-Invasive Bladder Cancer

2011 ◽  
Vol 17 (9) ◽  
pp. 2788-2798 ◽  
Author(s):  
Clement Mugabe ◽  
Yoshiyuki Matsui ◽  
Alan I. So ◽  
Martin E. Gleave ◽  
Jennifer H. E. Baker ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
In Vivo Evaluation ◽  
Intravesical Treatment ◽  
Muscle Invasive

Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. TPS531-TPS531 ◽  
Author(s):  
Andrew James Weickhardt ◽  
Farshad Foroudi ◽  
Shomik Sengupta ◽  
Laura Galletta ◽  
Alan Herschtal ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Molecular Genetic ◽  
Response To Therapy ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Immunological Parameters ◽  
Muscle Invasive

TPS531 Background: Pembrolizumab leads to responses in ~20% of metastatic bladder cancer patients. Irradiation of bladder cancer cells in-vitro and in-vivo leads to upregulation of PD-L1, and in immunocompetent mouse models blockade of PD-L1 leads to delayed tumour growth following irradiation. Randomised data from PACIFIC trial in NSCLC shows the addition of PD-L1 inhibition to chemoradiation significantly prolongs PFS. A trial of chemoradiotherapy with pembrolizumab will assess safety and synergy of the combination in localised bladder cancer. Methods: This pilot study enrols patients with maximally resected non-metastatic muscle invasive bladder cancer, who either wish for bladder preservation or are ineligible for cystectomy. This study will assess the safety and feasibility of combining pembrolizumab with chemoradiotherapy in ECOG 0-1 patients without contraindications to pembrolizumab. The study has enrolled 4 of a planned 30 patients. All patients treated with 64Gy of radiation therapy in 32 fractions over 6 weeks, 2 days. Cisplatin 35mg/m2 IV concurrently weekly for 6 doses with radiation. Pembrolizumab commences concurrently with radiation and is given 200mg IV q21 days for 7 doses. Surveillance cystoscopy is performed 12 & 24 weeks after the commencement of chemoradiotherapy to assess response to therapy. Patients will enter follow up with clinical assessment, cystoscopy and CT staging performed at intervals until close of study. The primary endpoint assessed will be safety, as defined by a satisfactorily low rate of unacceptable toxicity (G3-4 adverse events or failure of completion of planned chemotherapy and radiotherapy according to defined parameters). The secondary endpoint will be efficacy, as assessed by the proportion of patients achieving a best response of complete response based on the first two 12 and 24 week post chemoradiotherapy cystoscopic assessments. Exploratory analysis will include assessment of tumour histopathological, molecular, genetic and immunological parameters. It is expected that it will take two years to accrue the 30 patients across 5 Australian centres. NCT02662062. Clinical trial information: NCT02662062.

Therapy for Non-Muscle Invasive Bladder Cancer: HP-NAP

2012 ◽  
Vol 79 (2) ◽  
pp. 142-148 ◽  
Author(s):  
Daniele D'Agostino ◽  
Marco Racioppi ◽  
Alessio Filianoti ◽  
Luca Di Gianfrancesco ◽  
Gaia Codolo ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Recurrence ◽  
New Drugs ◽  
In Vivo Studies ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Ifn Γ ◽  
Muscle Invasive ◽  
Bladder Cancer Recurrence

Purpose Patients with non-muscle invasive bladder cancer recurrence after 2 induction courses of BCG are eligible for radical cystectomy. So, in the last years research to discover new drugs for the management of non-muscle invasive bladder cancer recurrence after failure of first and second line therapy is ongoing. In accordance to the results obtained with BCG, whose mechanism depends on the induction of the T helper 1 (TH1) immune response, we investigated the activity of a Toll-like receptor (TLR) 2 ligand, named Helicobacter Pylori Neutrophil Activating Protein (HP-NAP), that we recently demonstrated being able of enhancing the differentiation of Th1 cells, both in vitro and in vivo, because of its ability to create an IL-12 enriched milieu. Materials and Methods We show here, in a mouse model of bladder neoplasm implants, that local administration of HP-NAP decreases tumor growth by inducing tumor necrosis. Results The result is joined up with a massive cluster of both CD4+ and CD8+ IFN-γ+ cells, within neoplasm and regional lymph nodes. It is of note that HP-NAP-treated tumors show also a reduced vascularization due to the anti-angiogenic activity of IFN-γ induced by HP-NAP. Conclusions The present study suggests that the activity of HP-NAP against urothelial tumor burden warrants subsequent in vivo studies.

scholarly journals The Antitumor Effects of Plasma-Activated Saline on Muscle-Invasive Bladder Cancer Cells In Vitro and In Vivo Demonstrate Its Feasibility as a Potential Therapeutic Approach

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1042
Author(s):  
Hao Zhang ◽  
Jishen Zhang ◽  
Bo Guo ◽  
Hailan Chen ◽  
Dehui Xu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Cells ◽  
Culture Media ◽  
Invasive Bladder Cancer ◽  
Antitumor Effects ◽  
Muscle Invasive Bladder Cancer ◽  
Plasma Irradiation ◽  
Muscle Invasive

Muscle-invasive bladder cancer (MIBC) is a fast-growing and aggressive malignant tumor in urinary system. Since chemotherapy and immunotherapy are only useable with a few MIBC patients, the clinical treatment of MIBC still faces challenges. Here, we examined the feasibility of plasma-activated saline (PAS) as a fledgling therapeutic strategy for MIBC treatment. Our data showed that plasma irradiation could generate a variety of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in saline. In vivo tests revealed that pericarcinomatous tissue injection with PAS was effective at preventing subcutaneous bladder tumor growth, with no side effects to the visceral organs after long-term administration, as well as having no obvious influence on the various biochemistry indices of the blood in mice. The in vitro studies indicated that adding 30% PAS in cell culture media causes oxidative damage to the bladder transitional cells T24 and J82 through enhancing the intracellular ROS level, and eventually induces cancer cells’ apoptosis by activating the ROS-mediated Fas/CD95 pathway. Therefore, for an intracavity tumor, these initial observations suggest that the soaking of the tumor tissue with PAS by intravesical perfusion may be a novel treatment option for bladder cancer.

933 Establishment of a new orthotopic in vivo examinable model of non-muscle invasive bladder cancer using RT112 reporter cells

2016 ◽  
Vol 15 (3) ◽  
pp. e933
Author(s):  
A. Fragoulis ◽  
C. Fera ◽  
S. Schemmert ◽  
K. Strick ◽  
M. Anton ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Associating Graphene Oxide Derivatives to Treat Non-Muscle Invasive Bladder Cancer (NMIBC)

2021 ◽  
Vol 12 (1) ◽  
pp. 196-210
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Cancer Drug ◽  
Tumor Aggressiveness ◽  
Vegf Expression ◽  
Graphene Oxides ◽  
Muscle Invasive Bladder Cancer ◽  
The Usa ◽  
Muscle Invasive

According to estimates, there were 17,670 bladder cancer-associated deaths in the USA by 2019. Intravesical Bacillus Calmette-Guerin (BCG) instillation is used to treat non-muscle invasive bladder cancer (NMIBC). However, more than 40% of BCG administration cases fail to avoid NMIBC relapse and progression. Our aim is to use synthesized GO derivatives to enable the transport of doxorubicin (DOX), a conventional cancer drug, and siRNA to reduce VEGF. Several platforms were tested, and their effects on NMIBC progression were assessed in vivo based on histo- and immune analyses. siRNA and GO were covalently bonds to polyethyleneimine (PEI) and polyethylene glycol (PEG) (GO-PEG-PEI/siRNA). DOX bond to oxidized GO was also synthesized. Hybrids were administered in vivo (rats) against NMIBC. Histopathology results have shown that hybrids have reduced bladder cancer. The GO-COOH-DOX/GO-PEG-PEI/siRNA potentiated tumor aggressiveness (60%) reduction in animals that did not show signs of lesions. Immunohistochemistry results have shown that the GO hybrid reduced VEGF expression, increased endostatin levels, and low p53 levels were observed. Data analyzed in the current study have shown that hybrid graphene oxides were capable of reducing VEGF expression and have great potential to treat NMIBC.

scholarly journals Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non–muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin

2020 ◽  
Vol 78 (3) ◽  
pp. 387-399 ◽  
Author(s):  
Roger Li ◽  
Debasish Sundi ◽  
Jingsong Zhang ◽  
Youngchul Kim ◽  
Richard J. Sylvester ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Therapeutic Efficacy ◽  
Invasive Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo

2015 ◽  
Vol 9 (1) ◽  
pp. 53-62 ◽  
Author(s):  
Venkateshwar Madka ◽  
Altaf Mohammed ◽  
Qian Li ◽  
Yuting Zhang ◽  
Laura Biddick ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
P53 Signaling ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document